IP Library › Granted Patent US 12,227,580

Granted Patent B2

US 12,227,580 · App. 17/660,382 · Granted Feb 18, 2025

Antigen binding molecules that bind LIGHT

Inventor: Steve Holmes (Altrincham, GB)

Assignee: CENTESSA PHARMACEUTICALS (UK) LIMITED

C07K16/2875 A61K39/001136 A61K2039/505 C07K2317/51 C07K2317/55 C07K2317/565 C07K2317/76 C07K2317/92

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 12,227,580
App. No.: 17/660,382
Granted: Feb 18, 2025
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

The present invention relates to antigen binding molecules, including antibodies, fragments, and variants thereof, that bind to the TNF-related cytokine LIGHT (TNFSF14). The present invention also relates to methods of use of such antigen binding molecules in treating and/or preventing inflammatory disorders and immune disorders.

Claims (64)

1. A pharmaceutical composition for treatment of a LIGHT-mediated disease or disorder, the pharmaceutical composition comprising:

an anti-LIGHT antigen binding molecule, wherein the antigen binding molecule specifically binds to membrane-bound human LIGHT and has a higher affinity for membrane-bound human LIGHT compared to soluble human LIGHT, wherein the anti-LIGHT antigen binding molecule is selected from the group consisting of:

(a) an antibody comprising a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence DYEMH (SEQ ID NO: 38), a VHCDR2 comprising the amino acid sequence EIDPETGDTAYAQKFQG (SEQ ID NO: 147) and a VHCDR3 comprising the amino acid sequence ETDYFFDY (SEQ ID NO: 40); and a light chain variable region comprising a VLCDR1 comprising the amino acid sequence RASENIYGALN (SEQ ID NO: 34), a VLCDR2 comprising the amino acid sequence GATNLAE (SEQ ID NO: 35) and a VLCDR3 comprising the amino acid sequence QNVLTTPWT (SEQ ID NO: 36);

(b) an antibody comprising a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence DYEMH (SEQ ID NO: 6), a VHCDR2 comprising the amino acid sequence EIDPETGDTAYSQKFKG (SEQ ID NO: 7), a VHCDR3 comprising the amino acid sequence ETDYFFDY (SEQ ID NO: 8); and a light chain variable region comprising a VLCDR1 comprising the amino acid sequence GASENIYGALN (SEQ ID NO: 2), a VLCDR2 comprising the amino acid sequence GATNLAD (SEQ ID NO: 3) and a VLCDR3 comprising the amino acid sequence QNVLTTPWT (SEQ ID NO: 4);

(c) an antibody comprising a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence DYEMH (SEQ ID NO: 14), a VHCDR2 comprising the amino acid sequence EIDPETGDTAYSQKFKG (SEQ ID NO: 15) and a VHCDR3 comprising the amino acid sequence ETDYFFDY (SEQ ID NO: 16); and a light chain variable region comprising a VLCDR1 comprising the amino acid sequence GASENIYGALN (SEQ ID NO: 10), a VLCDR2 comprising the amino acid sequence GATNLAD (SEQ ID NO: 11) and a VLCDR3 comprising the amino acid sequence QNVLTTPWT (SEQ ID NO: 12);

(d) an antibody comprising a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence DYEMH (SEQ ID NO: 22), a VHCDR2 comprising the amino acid sequence EIDPETGDTAYSQKFQG (SEQ ID NO: 23) and a VHCDR3 comprising the amino acid sequence ETDYFFDY (SEQ ID NO: 24); and a light chain variable region comprising a VLCDR1 comprising the amino acid sequence GASENIYGALN (SEQ ID NO: 10), a VLCDR2 comprising the amino acid sequence GATNLAD (SEQ ID NO: 11) and a VLCDR3 comprising the amino acid sequence QNVLTTPWT (SEQ ID NO: 12);

(e) an antibody comprising a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence DYEMH (SEQ ID NO: 30), a VHCDR2 comprising the amino acid sequence EIDPETGDTAYAQKFQG (SEQ ID NO: 146) and a VHCDR3 comprising the amino acid sequence ETDYFFDY (SEQ ID NO: 32); and a light chain variable region comprising a VLCDR1 comprising the amino acid sequence GASENIYGALN (SEQ ID NO: 10), a VLCDR2 comprising the amino acid sequence GATNLAD (SEQ ID NO: 11) and a VLCDR3 comprising the amino acid sequence QNVLTTPWT (SEQ ID NO: 12);

(f) an antibody comprising a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence DYEMH (SEQ ID NO: 38), a VHCDR2 comprising the amino acid sequence EIDPETGDTAYAQKFQG (SEQ ID NO: 147) and a VHCDR3 comprising the amino acid sequence ETDYFFDY (SEQ ID NO: 40); and a light chain variable region comprising a VLCDR1 comprising the amino acid sequence GASENIYGALN (SEQ ID NO: 10), a VLCDR2 comprising the amino acid sequence GATNLAD (SEQ ID NO: 11) and a VLCDR3 comprising the amino acid sequence QNVLTTPWT (SEQ ID NO: 12);

(g) an antibody comprising a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence DYEMH (SEQ ID NO: 14), a VHCDR2 comprising the amino acid sequence EIDPETGDTAYSQKFKG (SEQ ID NO: 15) and a VHCDR3 comprising the amino acid sequence ETDYFFDY (SEQ ID NO: 16); and a light chain variable region comprising a VLCDR1 comprising the amino acid sequence GASENIYGALN (SEQ ID NO: 18), a VLCDR2 comprising the amino acid sequence GATNLAD (SEQ ID NO: 19) and a VLCDR3 comprising the amino acid sequence QNVLTTPWT (SEQ ID NO: 20);

(h) an antibody comprising a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence DYEMH (SEQ ID NO: 22), a VHCDR2 comprising the amino acid sequence EIDPETGDTAYSQKFQG (SEQ ID NO: 23) and a VHCDR3 comprising the amino acid sequence ETDYFFDY (SEQ ID NO: 24); and a light chain variable region comprising a VLCDR1 comprising the amino acid sequence GASENIYGALN (SEQ ID NO: 18), a VLCDR2 comprising the amino acid sequence GATNLAD (SEQ ID NO: 19) and a VLCDR3 comprising the amino acid sequence QNVLTTPWT (SEQ ID NO: 20);

(i) an antibody comprising a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence DYEMH (SEQ ID NO: 30), a VHCDR2 comprising the amino acid sequence EIDPETGDTAYAQKFQG (SEQ ID NO: 146) and a VHCDR3 comprising the amino acid sequence ETDYFFDY (SEQ ID NO: 32); and a light chain variable region comprising a VLCDR1 comprising the amino acid sequence GASENIYGALN (SEQ ID NO: 18), a VLCDR2 comprising the amino acid sequence GATNLAD (SEQ ID NO: 19) and a VLCDR3 comprising the amino acid sequence QNVLTTPWT (SEQ ID NO: 20);

(j) an antibody comprising a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence DYEMH (SEQ ID NO: 38), a VHCDR2 comprising the amino acid sequence EIDPETGDTAYAQKFQG (SEQ ID NO: 147) and a VHCDR3 comprising the amino acid sequence ETDYFFDY (SEQ ID NO: 40); and a light chain variable region comprising a VLCDR1 comprising the amino acid sequence GASENIYGALN (SEQ ID NO: 18), a VLCDR2 comprising the amino acid sequence GATNLAD (SEQ ID NO: 19) and a VLCDR3 comprising the amino acid sequence QNVLTTPWT (SEQ ID NO: 20);

(k) an antibody comprising a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence DYEMH (SEQ ID NO: 14), a VHCDR2 comprising the amino acid sequence EIDPETGDTAYSQKFKG (SEQ ID NO: 15) and a VHCDR3 comprising the amino acid sequence ETDYFFDY (SEQ ID NO: 16); and a light chain variable region comprising a VLCDR1 comprising the amino acid sequence GASENIYGALN (SEQ ID NO: 26), a VLCDR2 comprising the amino acid sequence GATNLAD (SEQ ID NO: 27) and a VLCDR3 comprising the amino acid sequence QNVLTTPWT (SEQ ID NO: 28);

(l) an antibody comprising a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence DYEMH (SEQ ID NO: 22), a VHCDR2 comprising the amino acid sequence EIDPETGDTAYSQKFQG (SEQ ID NO: 23) and a VHCDR3 comprising the amino acid sequence ETDYFFDY (SEQ ID NO: 24); and a light chain variable region comprising a VLCDR1 comprising the amino acid sequence GASENIYGALN (SEQ ID NO: 26), a VLCDR2 comprising the amino acid sequence GATNLAD (SEQ ID NO: 27) and a VLCDR3 comprising the amino acid sequence QNVLTTPWT (SEQ ID NO: 28);

(m) an antibody comprising a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence DYEMH (SEQ ID NO: 30), a VHCDR2 comprising the amino acid sequence EIDPETGDTAYAQKFQG (SEQ ID NO: 146) and a VHCDR3 comprising the amino acid sequence ETDYFFDY (SEQ ID NO: 32); and a light chain variable region comprising a VLCDR1 comprising the amino acid sequence GASENIYGALN (SEQ ID NO: 26), a VLCDR2 comprising the amino acid sequence GATNLAD (SEQ ID NO: 27) and a VLCDR3 comprising the amino acid sequence QNVLTTPWT (SEQ ID NO: 28);

(n) an antibody comprising a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence DYEMH (SEQ ID NO: 38), a VHCDR2 comprising the amino acid sequence EIDPETGDTAYAQKFQG (SEQ ID NO: 147) and a VHCDR3 comprising the amino acid sequence ETDYFFDY (SEQ ID NO: 40); and a light chain variable region comprising a VLCDR1 comprising the amino acid sequence GASENIYGALN (SEQ ID NO: 26), a VLCDR2 comprising the amino acid sequence GATNLAD (SEQ ID NO: 27) and a VLCDR3 comprising the amino acid sequence QNVLTTPWT (SEQ ID NO: 28);

(o) an antibody comprising a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence DYEMH (SEQ ID NO: 14), a VHCDR2 comprising the amino acid sequence EIDPETGDTAYSQKFKG (SEQ ID NO: 15) and a VHCDR3 comprising the amino acid sequence ETDYFFDY (SEQ ID NO: 16); and a light chain variable region comprising a VLCDR1 comprising the amino acid sequence RASENIYGALN (SEQ ID NO: 34), a VLCDR2 comprising the amino acid sequence GATNLAE (SEQ ID NO: 35) and a VLCDR3 comprising the amino acid sequence QNVLTTPWT (SEQ ID NO: 36);

(p) an antibody comprising a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence DYEMH (SEQ ID NO: 22), a VHCDR2 comprising the amino acid sequence EIDPETGDTAYSQKFQG (SEQ ID NO: 23) and a VHCDR3 comprising the amino acid sequence ETDYFFDY (SEQ ID NO: 24); and a light chain variable region comprising a VLCDR1 comprising the amino acid sequence RASENIYGALN (SEQ ID NO: 34), a VLCDR2 comprising the amino acid sequence GATNLAE (SEQ ID NO: 35) and a VLCDR3 comprising the amino acid sequence QNVLTTPWT (SEQ ID NO: 36);

(q) an antibody comprising a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence DYEMH (SEQ ID NO: 30), a VHCDR2 comprising the amino acid sequence EIDPETGDTAYAQKFQG (SEQ ID NO: 146) and a VHCDR3 comprising the amino acid sequence ETDYFFDY (SEQ ID NO: 32); and a light chain variable region comprising a VLCDR1 comprising the amino acid sequence RASENIYGALN (SEQ ID NO: 34), a VLCDR2 comprising the amino acid sequence GATNLAE (SEQ ID NO: 35) and a VLCDR3 comprising the amino acid sequence QNVLTTPWT (SEQ ID NO: 36);

(r) an antibody comprising a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence DSEIH (SEQ ID NO: 46), a VHCDR2 comprising the amino acid sequence EIDPETGGTAYNQKFKG (SEQ ID NO: 47), a VHCDR3 comprising the amino acid sequence ETDYFFDY (SEQ ID NO: 48); and a light chain variable region comprising a VLCDR1 comprising the amino acid sequence GASENIYGALN (SEQ ID NO: 42), a VLCDR2 comprising the amino acid sequence GATNLAD (SEQ ID NO: 43) and a VLCDR3 comprising the amino acid sequence QNVLSTPWT (SEQ ID NO: 44);

(s) an antibody comprising a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence DSEIH (SEQ ID NO: 54), a VHCDR2 comprising the amino acid sequence EIDPETGGTAYNQKFKG (SEQ ID NO: 55) and a VHCDR3 comprising the amino acid sequence ETDYFFDY (SEQ ID NO: 56); and a light chain variable region comprising a VLCDR1 comprising the amino acid sequence GASENIYGALN (SEQ ID NO: 50), a VLCDR2 comprising the amino acid sequence GATNLAD (SEQ ID NO: 51) and a VLCDR3 comprising the amino acid sequence QNVLSTPWT (SEQ ID NO: 52);

(t) an antibody comprising a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence DSEIH (SEQ ID NO: 62), a VHCDR2 comprising the amino acid sequence EIDPETGGTAYNQKFQG (SEQ ID NO: 63) and a VHCDR3 comprising the amino acid sequence ETDYFFDY (SEQ ID NO: 64); and a light chain variable region comprising a VLCDR1 comprising the amino acid sequence GASENIYGALN (SEQ ID NO: 50), a VLCDR2 comprising the amino acid sequence GATNLAD (SEQ ID NO: 51) and a VLCDR3 comprising the amino acid sequence QNVLSTPWT (SEQ ID NO: 52);

(u) an antibody comprising a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence DSEIH (SEQ ID NO: 70), a VHCDR2 comprising the amino acid sequence EIDPETGGTAYAQKFQG (SEQ ID NO: 71) and a VHCDR3 comprising the amino acid sequence ETDYFFDY (SEQ ID NO: 72); and a light chain variable region comprising a VLCDR1 comprising the amino acid sequence GASENIYGALN (SEQ ID NO: 50), a VLCDR2 comprising the amino acid sequence GATNLAD (SEQ ID NO: 51) and a VLCDR3 comprising the amino acid sequence QNVLSTPWT (SEQ ID NO: 52);

(v) an antibody comprising a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence DSEMH (SEQ ID NO: 78), a VHCDR2 comprising the amino acid sequence EIDPETGGTAYAQKFQG (SEQ ID NO: 79) and a VHCDR3 comprising the amino acid sequence ETDYFFDY (SEQ ID NO: 80); and a light chain variable region comprising a VLCDR1 comprising the amino acid sequence GASENIYGALN (SEQ ID NO: 50), a VLCDR2 comprising the amino acid sequence GATNLAD (SEQ ID NO: 51) and a VLCDR3 comprising the amino acid sequence QNVLSTPWT (SEQ ID NO: 52);

(w) an antibody comprising a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence DSEIH (SEQ ID NO: 54), a VHCDR2 comprising the amino acid sequence EIDPETGGTAYNQKFKG (SEQ ID NO: 55) and a VHCDR3 comprising the amino acid sequence ETDYFFDY (SEQ ID NO: 56); and a light chain variable region comprising a VLCDR1 comprising the amino acid sequence GASENIYGALN (SEQ ID NO: 58), a VLCDR2 comprising the amino acid sequence GATNLAD (SEQ ID NO: 59) and a VLCDR3 comprising the amino acid sequence QNVLSTPWT (SEQ ID NO: 60);

(x) an antibody comprising a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence DSEIH (SEQ ID NO: 62), a VHCDR2 comprising the amino acid sequence EIDPETGGTAYNQKFQG (SEQ ID NO: 63) and a VHCDR3 comprising the amino acid sequence ETDYFFDY (SEQ ID NO: 64); and a light chain variable region comprising a VLCDR1 comprising the amino acid sequence GASENIYGALN (SEQ ID NO: 58), a VLCDR2 comprising the amino acid sequence GATNLAD (SEQ ID NO: 59) and a VLCDR3 comprising the amino acid sequence QNVLSTPWT (SEQ ID NO: 60);

(y) an antibody comprising a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence DSEIH (SEQ ID NO: 70), a VHCDR2 comprising the amino acid sequence EIDPETGGTAYAQKFQG (SEQ ID NO: 71) and a VHCDR3 comprising the amino acid sequence ETDYFFDY (SEQ ID NO: 72); and a light chain variable region comprising a VLCDR1 comprising the amino acid sequence GASENIYGALN (SEQ ID NO: 58), a VLCDR2 comprising the amino acid sequence GATNLAD (SEQ ID NO: 59) and a VLCDR3 comprising the amino acid sequence QNVLSTPWT (SEQ ID NO: 60);

(z) an antibody comprising a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence DSEMH (SEQ ID NO: 78), a VHCDR2 comprising the amino acid sequence EIDPETGGTAYAQKFQG (SEQ ID NO: 79) and a VHCDR3 comprising the amino acid sequence ETDYFFDY (SEQ ID NO: 80); and a light chain variable region comprising a VLCDR1 comprising the amino acid sequence GASENIYGALN (SEQ ID NO: 58), a VLCDR2 comprising the amino acid sequence GATNLAD (SEQ ID NO: 59) and a VLCDR3 comprising the amino acid sequence QNVLSTPWT (SEQ ID NO: 60);

(aa) an antibody comprising a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence DSEIH (SEQ ID NO: 54), a VHCDR2 comprising the amino acid sequence EIDPETGGTAYNQKFKG (SEQ ID NO: 55) and a VHCDR3 comprising the amino acid sequence ETDYFFDY (SEQ ID NO: 56); and a light chain variable region comprising a VLCDR1 comprising the amino acid sequence GASENIYGALN (SEQ ID NO: 66), a VLCDR2 comprising the amino acid sequence GATNLAD (SEQ ID NO: 67) and a VLCDR3 comprising the amino acid sequence QNVLSTPWT (SEQ ID NO: 68);

(ab) an antibody comprising a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence DSEIH (SEQ ID NO: 62), a VHCDR2 comprising the amino acid sequence EIDPETGGTAYNQKFQG (SEQ ID NO: 63) and a VHCDR3 comprising the amino acid sequence ETDYFFDY (SEQ ID NO: 64); and a light chain variable region comprising a VLCDR1 comprising the amino acid sequence GASENIYGALN (SEQ ID NO: 66), a VLCDR2 comprising the amino acid sequence GATNLAD (SEQ ID NO: 67) and a VLCDR3 comprising the amino acid sequence QNVLSTPWT (SEQ ID NO: 68);

(ac) an antibody comprising a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence DSEIH (SEQ ID NO: 70), a VHCDR2 comprising the amino acid sequence EIDPETGGTAYAQKFQG (SEQ ID NO: 71) and a VHCDR3 comprising the amino acid sequence ETDYFFDY (SEQ ID NO: 72); and a light chain variable region comprising a VLCDR1 comprising the amino acid sequence GASENIYGALN (SEQ ID NO: 66), a VLCDR2 comprising the amino acid sequence GATNLAD (SEQ ID NO: 67) and a VLCDR3 comprising the amino acid sequence QNVLSTPWT (SEQ ID NO: 68);

(ad) an antibody comprising a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence DSEMH (SEQ ID NO: 78), a VHCDR2 comprising the amino acid sequence EIDPETGGTAYAQKFQG (SEQ ID NO: 79) and a VHCDR3 comprising the amino acid sequence ETDYFFDY (SEQ ID NO: 80); and a light chain variable region comprising a VLCDR1 comprising the amino acid sequence GASENIYGALN (SEQ ID NO: 66), a VLCDR2 comprising the amino acid sequence GATNLAD (SEQ ID NO: 67) and a VLCDR3 comprising the amino acid sequence QNVLSTPWT (SEQ ID NO: 68);

(ae) an anti-LIGHT antigen binding molecule comprising a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence DSEIH (SEQ ID NO: 54), a VHCDR2 comprising the amino acid sequence EIDPETGGTAYNQKFKG (SEQ ID NO: 55) and a VHCDR3 comprising the amino acid sequence ETDYFFDY (SEQ ID NO: 56); and a light chain variable region comprising a VLCDR1 comprising the amino acid sequence RASENIYGALN (SEQ ID NO: 74), a VLCDR2 comprising the amino acid sequence GATNLAE (SEQ ID NO: 75) and a VLCDR3 comprising the amino acid sequence QNVLSTPWT (SEQ ID NO: 76);

(af) an antibody comprising a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence DSEIH (SEQ ID NO: 62), a VHCDR2 comprising the amino acid sequence EIDPETGGTAYNQKFQG (SEQ ID NO: 63) and a VHCDR3 comprising the amino acid sequence ETDYFFDY (SEQ ID NO: 64); and a light chain variable region comprising a VLCDR1 comprising the amino acid sequence RASENIYGALN (SEQ ID NO: 74), a VLCDR2 comprising the amino acid sequence GATNLAE (SEQ ID NO: 75) and a VLCDR3 comprising the amino acid sequence QNVLSTPWT (SEQ ID NO: 76);

(ag) an antibody comprising a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence DSEIH (SEQ ID NO: 70), a VHCDR2 comprising the amino acid sequence EIDPETGGTAYAQKFQG (SEQ ID NO: 71) and a VHCDR3 comprising the amino acid sequence ETDYFFDY (SEQ ID NO: 72); and a light chain variable region comprising a VLCDR1 comprising the amino acid sequence RASENIYGALN (SEQ ID NO: 74), a VLCDR2 comprising the amino acid sequence GATNLAE (SEQ ID NO: 75) and a VLCDR3 comprising the amino acid sequence QNVLSTPWT (SEQ ID NO: 76); and

(ah) an antibody comprising a heavy chain variable region comprising a VHCDR1 comprising the amino acid sequence DSEMH (SEQ ID NO: 78), a VHCDR2 comprising the amino acid sequence EIDPETGGTAYAQKFQG (SEQ ID NO: 79) and a VHCDR3 comprising the amino acid sequence ETDYFFDY (SEQ ID NO: 80); and a light chain variable region comprising a VLCDR1 comprising the amino acid sequence RASENIYGALN (SEQ ID NO: 74), a VLCDR2 comprising the amino acid sequence GATNLAE (SEQ ID NO: 75) and a VLCDR3 comprising the amino acid sequence QNVLSTPWT (SEQ ID NO: 76).

2. The pharmaceutical composition for treatment of a LIGHT-mediated disease or disorder of claim 1 , wherein the anti-LIGHT antigen binding molecule has from about 10 times to about 100 times higher affinity for membrane-bound human LIGHT compared to soluble human LIGHT.

3. The pharmaceutical composition for treatment of a LIGHT-mediated disease or disorder of claim 1 , wherein the LIGHT-mediated disease or disorder is a chronic inflammatory autoimmune disease, an inflammatory disorder or disease, or an autoimmune disorder or disease.

4. The pharmaceutical composition for treatment of a LIGHT-mediated disease or disorder of claim 3 , wherein the chronic inflammatory autoimmune disease, the inflammatory disorder or disease, or the autoimmune disorder or disease is inflammatory bowel disease (IBD).

5. The pharmaceutical composition for treatment of a LIGHT-mediated disease or disorder of claim 4 , wherein the IBC is Crohn's disease (CD), ulcerative colitis (US), collagenous colitis, lymphocytic colitis, ischemic colitis, diversion colitis, Behcet's disease, and indeterminate colitis.

6. The pharmaceutical composition for treatment of a LIGHT-mediated disease or disorder of claim 1 , wherein the anti-LIGHT antigen binding molecule comprises:

a heavy chain variable region having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence selected from the group consisting of SEQ ID NO: 5, SEQ ID NO: 13, SEQ ID NO: 21, SEQ ID NO: 29, SEQ ID NO: 37, SEQ ID NO: 45, SEQ ID NO: 53, SEQ ID NO: 61, SEQ ID NO: 69, and SEQ ID NO: 77; and/or a light chain variable region having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence selected from the group consisting of consisting SEQ ID NO: 1, SEQ ID NO: 9, SEQ ID NO: 17, SEQ ID NO: 25, SEQ ID NO: 33, SEQ ID NO: 41, SEQ ID NO: 49, SEQ ID NO: 57, SEQ ID NO: 65, and SEQ ID NO: 73.

7. A method of treating a LIGHT-mediated disease or disorder in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim 1 .

8. A method of treating an inflammatory disorder or disease or an autoimmune disorder or disease in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim 1 .

9. A method of inhibiting interferon-gamma release by administering to a subject in need thereof a therapeutically effective amount of the pharmaceutical composition of claim 1 .

10. A pharmaceutical composition for treatment of a LIGHT-mediated disease or disorder, the pharmaceutical composition comprising:

an anti-LIGHT antigen binding molecule, wherein the anti-LIGHT antigen binding molecule is an antibody that specifically binds to membrane-bound human LIGHT and is selected from the group consisting of: 3B04, 3D12, 3B04_var1, 3B04_var2, 3B04_var3, 3B04_var4, 3B04_var5, 3B04_var6, 3B04_var7, 3B04_var8, 3B04_var9, 3B04_var10, 3B04_var11, 3B04_var12, 3B04_var13, 3B04_var14, 3B04_var15, 3B04_var16, 3D12_var1, 3D12_var2, 3D12_var3, 3D12_var4, 3D12_var5, 3D12_var6, 3D12_var7, 3D12_var8, 3D12_var9, 3D12_var10, 3D12_var11, 3D12_var12, 3D12_var13, 3D12_var14, 3D12_var15 and 3D12_var16.

11. The pharmaceutical composition for treatment of a LIGHT-mediated disease or disorder of claim 10 , wherein the anti-LIGHT antigen binding molecule has from about 10 times to about 100 times higher affinity for membrane-bound human LIGHT compared to soluble human LIGHT.

12. The pharmaceutical composition for treatment of a LIGHT-mediated disease or disorder of claim 10 , wherein the LIGHT-mediated disease or disorder is a chronic inflammatory autoimmune disease, an inflammatory disorder or disease, or an autoimmune disorder or disease.

13. The pharmaceutical composition for treatment of a LIGHT-mediated disease or disorder of claim 12 , wherein the chronic inflammatory autoimmune disease, the inflammatory disorder or disease, or the autoimmune disorder or disease is inflammatory bowel disease (IBD).

14. The pharmaceutical composition for treatment of a LIGHT-mediated disease or disorder of claim 13 , wherein the IBC is Crohn's disease (CD), ulcerative colitis (US), collagenous colitis, lymphocytic colitis, ischemic colitis, diversion colitis, Behcet's disease, and indeterminate colitis.

15. A method of treating a LIGHT-mediated disease or disorder in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim 10 .

16. A method of treating an inflammatory disorder or disease or an autoimmune disorder or disease in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim 10 .

17. A method of inhibiting interferon-gamma release by administering to a subject in need thereof a therapeutically effective amount of the pharmaceutical composition of claim 10 .

18. A nucleic acid encoding an anti-LIGHT antigen binding molecule comprising:

19. The nucleic acid of claim 18 , wherein the anti-LIGHT antigen binding molecule is an antibody.

20. A plasmid comprising the nucleic acid of claim 18 .

21. A vector comprising the nucleic acid of claim 18 .

22. A method of producing an anti-LIGHT antigen binding molecule comprising:

transfecting a host cell using a vector comprising the nucleic acid of claim 18 ;

culturing the transfected host cell in a cell culture medium under conditions to express the anti-LIGHT antigen binding molecule encoded by the nucleic acid of claim 18 .

23. The method of claim 22 , further comprising obtaining the anti-LIGHT antigen binding molecule from supernatant of the cell culture medium.

24. The method of claim 22 , further comprising obtaining the anti-LIGHT antigen binding molecule from supernatant of the cell culture medium.

Assignments (4)

RELEASE OF SECURITY INTEREST Recorded Jun 24, 2026

From: OXFORD FINANCE LLC

To: CENTESSA PHARMACEUTICALS (UK) LIMITED

Reel/Frame 075069/0879 →

SECURITY INTEREST Recorded Dec 31, 2024

From: CENTESSA PHARMACEUTICALS (UK) LIMITED

To: OXFORD FINANCE LLC

Reel/Frame 069708/0039 →

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 31, 2023

From: HOLMES, STEVE

To: CAPELLA BIOSCIENCE LTD

Reel/Frame 065403/0606 →

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 28, 2023

From: CAPELLA BIOSCIENCE LTD

To: CENTESSA PHARMACEUTICALS (UK) LIMITED

Reel/Frame 065056/0399 →

Continuity (3)

Division 16256688 · Jan 24, 2019

Provisional Application 62621346 · Jan 24, 2018

Related Publication 20230035798A1 · Feb 2, 2023

References Cited (75)

US 6635743B1 · Ebner et al. · 2003 [cited by applicant]

US 6998108B1 · Ware · 2006 [cited by applicant]

US 7575745B2 · Ware · 2009 [cited by applicant]

US 7964190B2 · Ebner et al. · 2011 [cited by applicant]

US 8058402B2 · Granger et al. · 2011 [cited by applicant]

US 8461307B2 · Granger et al. · 2013 [cited by applicant]

US 8524869B2 · Smith et al. · 2013 [cited by applicant]

US 8734795B2 · Wang et al. · 2014 [cited by applicant]

US 8974787B2 · Granger et al. · 2015 [cited by applicant]

US 9771419B2 · Granger et al. · 2017 [cited by applicant]

US 20030104477A1 · Buechler et al. · 2003 [cited by applicant]

US 20130345406A1 · Van De Winkel et al. · 2013 [cited by applicant]

US 20150118222A1 · Levy et al. · 2015 [cited by applicant]

US 20160214954A1 · O'Neill et al. · 2016 [cited by applicant]

US 20170029521A1 · Van De Winkel et al. · 2017 [cited by applicant]

US 20170051351A1 · Hakonarson et al. · 2017 [cited by applicant]

US 20170051352A1 · Hakonarson et al. · 2017 [cited by applicant]

US 20170058037A1 · Croft et al. · 2017 [cited by applicant]

US 20170165230A1 · Rudd et al. · 2017 [cited by applicant]

US 20170232104A1 · Schnieders et al. · 2017 [cited by applicant]

US 20180016345A1 · Croft et al. · 2018 [cited by applicant]

EP 1336619A2 · 2003 [cited by applicant]

EP 1274840B1 · 2007 [cited by applicant]

EP 1674575B1 · 2010 [cited by applicant]

EP 1003782B1 · 2011 [cited by applicant]

EP 2292663B1 · 2013 [cited by applicant]

EP 2666787A1 · 2013 [cited by applicant]

EP 2411412B1 · 2015 [cited by applicant]

EP 3041831A1 · 2016 [cited by applicant]

EP 3060251A1 · 2016 [cited by applicant]

EP 2484696B1 · 2017 [cited by applicant]

EP 3337465A1 · 2018 [cited by applicant]

EP 3337509A1 · 2018 [cited by applicant]

EP 2830658B1 · 2018 [cited by applicant]

EP 3431104A1 · 2019 [cited by applicant]

JP 2012507299A · 2012 [cited by applicant]

WO WO2003089575A2 · 2003 [cited by applicant]

WO WO2008027338A2 · 2008 [cited by applicant]

WO WO2008083169A2 · 2008 [cited by applicant]

WO WO2009039310A2 · 2009 [cited by applicant]

WO WO2010111180A1 · 2010 [cited by applicant]

WO WO2013148686A2 · 2013 [cited by applicant]

WO WO2013148350A2 · 2013 [cited by applicant]

WO WO2015035212A1 · 2015 [cited by applicant]

WO WO2015061752A1 · 2015 [cited by applicant]

WO WO2015107331A2 · 2015 [cited by applicant]

WO WO2015155738A2 · 2015 [cited by applicant]

WO WO2016127059A2 · 2016 [cited by applicant]

WO WO2017035010A1 · 2017 [cited by applicant]

WO WO2017035017A1 · 2017 [cited by applicant]

International Search Report mailed Aug. 2, 2018 in connection with International Application No. PCT/GB2018/050203 (7 pgs.). [cited by applicant]

Search Report under Section 17 for GB Application No. GB1701194.1 dated Nov. 15, 2017 (2 pgs.). [cited by applicant]

P. Pitaksajjakul et al., “Fab MAbs specific to HA of influenza virus with H5N1 neutralizing activity selected from Immunized chicken phage library”, Biochemical and Biophysical Research Communications, 395 (2010) 496-50… [cited by applicant]

Ware, Carl F., “Targeting lymphocyte activation through the lymphotoxin and LIGHT pathways”, Immunol Rev. Jun. 2008; 223: 186-201 (29 pgs.). [cited by applicant]

Wu, H., et al., “Humanization of a Murine Monoclonal Antibody by Simultaneous Optimization of Framework and CDR Residues”. J. Mol. Biol. (1999) 294, 151-162 (12 pgs.). [cited by applicant]

Yang, J., et al.(2011) Therapeutic Potential and Challenges of Targeting Receptor Tyrosine Kinase ROR1 with Monoclonal Antibodies in B-Cell Malignancies. PLoS ONE 6(6): e21018. doi:10.1371/journal.pone.0021018. [cited by applicant]

Casset et al. ((2003) BBRC 307, 198-205 (Year: 2003). [cited by applicant]

Padlan et al. (PNAS 1989, 86:5938-5942) (Year: 1989). [cited by applicant]

Amminmaki et al. (JBC 2001,276:36687-36694) (Year: 2001). [cited by applicant]

Ward et al. (Nature 341 :544-546 ( 1989)) (Year: 1989). [cited by applicant]

Smith-Gill et al. (J. Immunol. 139:4135-4144 (1987)) (Year: 1987). [cited by applicant]

Kumar et al. (J. Biol. Chem. 275:35129-35136 (2000)) (Year: 2000). [cited by applicant]

Lloyd et al. Protein Engineering, Design & Selection 2009, 22: 159-168 (Year: 2009). [cited by applicant]

Chen, Yvonne et al. Selection and Analysis of an Optimized Anti-VEGF Antibody: Crystal Structure of an Affinity-matured Fab in Complex With Antigen. Journal of Molecular Biology 293(4):865-881 (1999). [cited by applicant]

De Pascalis, Roberto et al. Grafting of “Abbreviated” Complementarity-Determining Regions Containing Specificity-Determining Residues Essential for Ligand Contact to Engineer a Less Immunogenic Humanized Monoclonal Anti… [cited by applicant]

Maccallum, Robert M et al. Antibody-Antigen Interactions: Contact Analysis And Binding Site Topography. Journal of Molecular Biology 262(5):732-745 (1996). [cited by applicant]

Piche-Nicholas, Nicole M. et al. Changes In Complementarity-Determining Regions Significantly Alter IgG Binding To The Neonatal Fc Receptor (FcRn) And Pharmacokinetics. Monoclonal Antibodies 10(1):81-94 (2018). [cited by applicant]

Rudikoff, Stuart et al. Single Amino Acid Substitution Altering Antigen-binding Specificity. PNAS USA 79(6):1979-1983 (1982). [cited by applicant]

Schroeder, Harry W et al. Structure and Function of Immunoglobulins. Journal of Allergy and Clinical Immunology 125(2 Suppl 2):S41-S52 (2010). [cited by applicant]

U.S. Appl. No. 16/256,688 Notice of Allowance dated Dec. 22, 2021. [cited by applicant]

U.S. Appl. No. 16/256,688 Office Action dated Jun. 7, 2021. [cited by applicant]

U.S. Appl. No. 16/480,367 Final Office Action dated Mar. 23, 2023. [cited by applicant]

U.S. Appl. No. 16/480,367 Non-Final Office Action dated Jul. 8, 2022. [cited by applicant]

U.S. Appl. No. 16/480,367 Notice of Allowance dated Jul. 3, 2023. [cited by applicant]

Vajdos, et al. Comprehensive functional maps of the antigen-binding site of an anti-ErbB2 antibody obtained with shotgun scanning mutagenesis. Journal of Molecular Biology 320(2):415-428 (2002). [cited by applicant]